deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT02768337

Cambridge Brain Mets Trial 1 (CamBMT1)

Cambridge Brain Mets Trial 1: A Proof-of-principle Phase 1b/Randomised Phase 2 Study of Afatinib Penetration Into Cerebral Metastases for Patients Undergoing Neurosurgical Resection, Both With and Without Prior Low-dose, Targeted Radiotherapy

Sponsor: Boehringer Ingelheim

Conditions Advanced Breast Cancer Advanced Lung Cancer Brain Cancer Breast Cancer Lung Cancer
Interventions 2 Gy targeted radiotherapy 4 Gy targeted radiotherapy Afatinib
Updated 11 times since 2017 Last updated: Jan 30, 2024 Started: Mar 10, 2015 Primary completion: Aug 12, 2020 Completion: Aug 12, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow recruitment

Other terminated trials from Boehringer Ingelheim

See all terminations from Boehringer Ingelheim

Other Advanced Breast Cancer trials with similar outcome

Browse all Advanced Breast Cancer trials

This PHASE1/PHASE2 trial investigates Advanced Breast Cancer and Advanced Lung Cancer and is currently terminated or withdrawn. Boehringer Ingelheim leads this study, which shows 11 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Mar 2017 · 59 days · monthly snapshotRecruiting~Mar 2017 – ~Jun 2018 · 15 months · monthly snapshotRecruiting~Jun 2018 – ~Jan 2019 · 7 months · monthly snapshotRecruiting~Jan 2019 – ~Feb 2020 · 13 months · monthly snapshotRecruiting~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshotRecruiting~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshotRecruiting~Feb 2021 – ~Feb 2023 · 24 months · monthly snapshotRecruiting~Feb 2023 – ~Feb 2024 · 12 months · monthly snapshotUnknown Status~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 23 months · monthly snapshotTerminated

Change History

11 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Feb 2024 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

    Status: Unknown Status → Terminated

  4. Feb 2023 — Feb 2024 [monthly]

    Unknown Status PHASE1_PHASE2

    Status: Recruiting → Unknown Status

  5. Feb 2021 — Feb 2023 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 6 earlier versions

  1. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE1_PHASE2

  2. Feb 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  3. Jan 2019 — Feb 2020 [monthly]

    Recruiting PHASE1_PHASE2

  4. Jun 2018 — Jan 2019 [monthly]

    Recruiting PHASE1_PHASE2

  5. Mar 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  6. Jan 2017 — Mar 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Mar 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Boehringer Ingelheim
  • Cambridge University Hospitals NHS Foundation Trust
  • Cancer Research UK
  • The Brain Tumour Charity
  • University of Cambridge
Data source: Cambridge University Hospitals NHS Foundation Trust

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations